10173 Long-Term Therapy of Elagolix  + Add-Back Therapy in Women with Endometriosis-Associated Pain for 48 Months: Update on Bone Mineral Density

To report the 48-month bone mineral density data of a phase 3 study evaluating the long-term safety of elagolix 200 mg twice daily (ELA) with add-back therapy (AB, estradiol 1 mg/0.5 mg norethindrone acetate) for treatment of endometriosis-associated pain (EAP; NCT03213457).

Source: The Journal of Minimally Invasive Gynecology - October 27, 2023 Category: OBGYN Authors: JH Kim, JA Simon, P Miller, J Ng, A Chan, J Thomas, M Snabes Source Type: research